Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axelopran and Pembrolizumab in R/M HNSCC Patients Taking Opioids
NCT07662720Phase 2Not yet recruiting
- Sponsor
- Glycyx Therapeutics
- Start
- Jul 2026
- Primary completion
- Aug 2027
01
Overview
Phase 2, open-label, single-arm trial of axelopran in head and neck squamous cell carcinoma (HNSCC), sponsored by Glycyx Therapeutics. Primary endpoint: Safety and Tolerability at 12 weeks. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
axelopran
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT07662720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07662720.